https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Rationale for FDA’s Position on the Use of Cefazolin Breakpoints as a Surrogate for Determining Breakpoints for Oral Cephalosporins for the Treatment of Uncomplicated Urinary Tract Infections

Rationale for FDA’s Position on the Use of Cefazolin Breakpoints as a Surrogate for Determining Breakpoints for Oral Cephalosporins for the Treatment of Uncomplicated Urinary Tract Infections

Rationale for FDA’s Position on the Use of Cefazolin Breakpoints as a Surrogate for Determining Breakpoints for Oral Cephalosporins for the Treatment of Uncomplicated Urinary Tract Infections

administrator

Related Articles